Background: GDF-15, a member of the superfamily of transforming GF beta, regulates pathways of inflammation and apoptosis in both short-term and long-term tissue injury. Among novel biomarkers is GDF-15, which is used to diagnose chronic heart failure conditions. LVEF is associated with increased end diastolic diameter, increase in LV mass index, and increased GDF-15. Objective: For assessing the validity of the GDF-15 test to predict CHF onset in people with coronary atherosclerosis. Subjects and methods: Our research was done on sixty-nine subjects, who were categorized as the following: 23 patients with CAD, 23 patients who developed CHF on top of CAD according to the revised Framingham criteria, and 23 subjects who represented the control group. CAD was evidenced by history of MI or PCI or CABG or positive treadmill or imaging stress test or coronary angiography (CA) revealing ≥50% stenosis in ≥1 coronary vessels. Results: Although there was no age difference between the CAD and CHF groups, there were high statistical significance difference regarding age among studied groups. However, no statistical significance difference was found regarding gender in the study groups. Smoking-related differences between the two groups and the control group were statistically significant, but not those between the CAD and CHF groups. Although there was a very statistically significant discrepancy between both the CAD and CHF groups and the control group, there was no a statistically significant in comparing hypertension between the CAD and CHF groups. There was not a significant difference in terms of DM between the CAD and CHF groups, however there was a statistically significant difference between the two groups and the control group. Conclusion: Our findings suggest that GDF-15 might be a valuable biomarker for predicting HF onset in CAD patients. GDF-15 levels were highly significantly different among CAD patients when compared to persons in good condition.